Efficacy and Safety of Short-term Administration of Aerosolized Recombinant Human Deoxyribonuclease in Patients with Cystic Fibrosis
Bonnie W. Ramsey(Seattle Children's Hospital), Jay D. Eisenberg(Oregon Health & Science University), Henry L. Dorkin(Boston Children's Hospital), Andrew A. Colin(Seattle Children's Hospital), Daniel V. Schidlow(Temple University), Ivan R. Harwood(University of California San Diego), Moira L. Aitken(University of Washington), R L Gibson(Seattle Children's Hospital), Susan J. Astley(Jikei University School of Medicine)
Cited by 234
Related Papers
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
|New England Journal of Medicine|1999|1.3k
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> Mutation
|New England Journal of Medicine|2010|802
DIAGNOSING THE FULL SPECTRUM OF FETAL ALCOHOL-EXPOSED INDIVIDUALS: INTRODUCING THE 4-DIGIT DIAGNOSTIC CODE
|Alcohol and Alcoholism|2000|532